Analysis Quality & compliance

UK and German device safety notices: what QA can and can't learn from the public lists

MHRA listed eight field safety notices for 9–13 November while BfArM posted six more. Public entries say little, so the real work happens in your own vigilance and supplier-control processes.

VigiEye editorial · Wed 18 Nov 2026

What happened

On 17 November 2026 the MHRA published its weekly list of device Field Safety Notices (FSNs) for 9–13 November. It contains eight notices. The manufacturers named include Boston Scientific, Brainlab, Medtronic, Siemens Healthcare and Ortho-Clinical Diagnostics. The MHRA publishes the list for information only. The records do not say which products the eight notices cover or what problems they describe.

Germany's BfArM was active in the same days. On 16 and 17 November it posted six urgent field safety notices: Philips (IntraSight Plus ultrasound system), Medtronic (Vanta implantable neurostimulator), Arthrex (NanoNeedle Scope), Urovision (VISIO-WEB WEBSINGER catheter), Intelerad (InteleShare imaging software) and Hitachi (cobas c 303 clinical chemistry analyser). In each case the public entry points to the manufacturer's own advisory, or gives no detail on the problem or required actions.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →